F. O'Harte

发表

Characterisation and biological activity of Glu3 amino acid substituted GIP receptor antagonists.

N. Irwin, P. Flatt, B. Green, 2007, Archives of biochemistry and biophysics.

Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy – A review

P. Flatt, F. O'Harte, J. Conlon, 2021, Peptides.

Isolation and primary structure of urotensin II from the brain of a tetrapod, the frog Rana ridibunda.

H. Vaudry, D. Smith, J. Conlon, 1992, Biochemical and biophysical research communications.

Effects on glucose homeostasis and insulin secretion of long term activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor by N-AcGIP(LysPAL37) in normal mice

N. Irwin, P. Flatt, B. Green, 2006, Peptides.

Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotrophic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice.

N. Irwin, P. Flatt, B. Green, 2006, The Journal of endocrinology.

Ablation of glucagon receptor signaling by peptide-based glucagon antagonists improves glucose tolerance in high fat fed mice

N. Irwin, F. O'Harte, Z. Franklin, 2014, Peptides.

Effects of short-term chemical ablation of glucagon signalling by peptide-based glucagon receptor antagonists on insulin secretion and glucose homeostasis in mice.

N. Irwin, F. O'Harte, Z. Franklin, 2014, Biological chemistry.

Detection of glycated gastric inhibitory polypeptide within the intestines of diabetic obese (ob/ob) mice

P. Flatt, M. Mooney, L. Morgan, 2001, Endocrine.

Evaluation of the antidiabetic activity of DPP IV resistant N-terminally modified versus mid-chain acylated analogues of glucose-dependent insulinotropic polypeptide.

N. Irwin, P. Flatt, B. Green, 2006, Biochemical pharmacology.

Development and therapeutic potential of incretin hormone analogues for type 2 diabetes

N. Irwin, P. Flatt, B. Green, 2005 .

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

P. Flatt, V. Gault, F. O'Harte, 2003, Biochemical and biophysical research communications.

Glucose-dependent insulinotropic polypeptide (GIP): anti-diabetic and anti-obesity potential?

P. Flatt, V. Gault, F. O'Harte, 2003, Neuropeptides.

Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice

N. Irwin, P. Flatt, P. McClean, 2007, Diabetologia.

Structural characterization of tachykinins (neuropeptide gamma, neurokinin A, and substance P) from a reptile, Alligator mississipiensis.

J. Conlon, F. O'Harte, Y. Wang, 1992, General and comparative endocrinology.

Development of a specific radioimmunoassay for vitamin B12 and its application in the diagnosis of cobalt deficiency in sheep

D. Kennedy, F. O'Harte, D. Rice, 1990, Veterinary Research Communications.

Blockade of gastric inhibitory polypeptide (GIP) action as a novel means of countering insulin resistance in the treatment of obesity-diabetes

N. Irwin, P. Flatt, V. Gault, 2019, Peptides.

Comparison of the anti‐diabetic effects of GIP‐ and GLP‐1‐receptor activation in obese diabetic (ob/ob) mice: studies with DPP IV resistant N‐AcGIP and exendin(1–39)amide

N. Irwin, P. Flatt, B. Green, 2007, Diabetes/metabolism research and reviews.

NMR and Alanine Scan Studies of Glucose-dependent Insulinotropic Polypeptide in Water*

P. Flatt, J. Malthouse, J. Parker, 2006, Journal of Biological Chemistry.

desHis¹Glu⁹-glucagon-[mPEG] and desHis¹Glu⁹(Lys³⁰PAL)-glucagon: long-acting peptide-based PEGylated and acylated glucagon receptor antagonists with potential antidiabetic activity.

N. Irwin, F. O'Harte, Z. Franklin, 2013, European journal of pharmacology.

Metabolic effects of combined glucagon receptor antagonism and glucagon-like peptide-1 receptor agonism in high fat fed mice.

N. Irwin, P. Flatt, R. Lafferty, 2022, Biochimie.

Two novel glucagon receptor antagonists prove effective therapeutic agents in high‐fat‐fed and obese diabetic mice

N. Irwin, F. O'Harte, Z. Franklin, 2014, Diabetes, obesity & metabolism.

Characterisation of structurally modified analogues of glucagon as potential glucagon receptor antagonists

N. Irwin, F. O'Harte, Z. Franklin, 2013, Molecular and Cellular Endocrinology.

Characterization of a Novel Glucose-Responsive Insulin-Secreting Cell Line, BRIN-BD11, Produced by Electrofusion

E. Ah-Sing, P. Flatt, F. O'Harte, 1996, Diabetes.

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

N. Irwin, P. Flatt, P. Flatt, 2013, International Journal of Obesity.

A stable analogue of glucose-dependent insulinotropic polypeptide, GIP(LysPAL16), enhances functional differentiation of mouse embryonic stem cells into cells expressing islet-specific genes and hormones

P. Flatt, L. Marenah, F. O'Harte, 2006, Biological chemistry.

Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus.

N. Irwin, P. Flatt, V. Gault, 2014, European journal of pharmacology.

A novel DPP IV-resistant C-terminally extended glucagon analogue exhibits weight-lowering and diabetes-protective effects in high-fat-fed mice mediated through glucagon and GLP-1 receptor activation

N. Irwin, P. Flatt, V. Gault, 2014, Diabetologia.

Purification and characterization of insulin, glucagon, and two glucagon-like peptides with insulin-releasing activity from the pancreas of the toad, Bufo marinus.

P. F. Nielsen, J. Conlon, F. O'Harte, 1998, Endocrinology.

Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice

N. Irwin, P. Flatt, R. Lafferty, 2022, The Journal of endocrinology.

Evaluation of glycated glucagon-like peptide-1(7-36)amide in intestinal tissue of normal and diabetic animal models.

P. Flatt, M. Mooney, F. O'Harte, 2002, Biochimica et biophysica acta.

Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.

C. Bailey, N. Irwin, P. Flatt, 2007, American journal of physiology. Endocrinology and metabolism.

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

C. Bailey, N. Irwin, P. Flatt, 2009, Biochemical pharmacology.

Measurement of T-kinin in rat plasma using a specific radioimmunoassay

D. Smith, J. Conlon, F. O'Harte, 1992, Regulatory Peptides.

Methylmalonic acid in the diagnosis of cobalt deficiency in barley-fed lambs

D. Kennedy, F. O'Harte, D. Rice, 1989, British Journal of Nutrition.

Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents.

P. Flatt, B. Green, V. Gault, 2004, Current pharmaceutical design.

Methylmalonyl-CoA mutase (EC 5.4.99.2) and methionine synthetase (EC 2.1.1.13) in the tissues of cobalt–vitamin B12 deficient sheep

D. Kennedy, A. Molloy, F. O'Harte, 1990, British Journal of Nutrition.

Sequential changes in propionate metabolism during the development of cobalt/vitamin B12 deficiency in sheep

D. Kennedy, F. O'Harte, D. Rice, 1991, Biological Trace Element Research.

Purification and characterization of urotensin II and parvalbumin from an elasmobranch fish, Scyliorhinus canicula (common dogfish).

N. Hazon, D. Smith, J. Conlon, 1992, Neuroendocrinology.

Conformational, receptor interaction and alanine scan studies of glucose-dependent insulinotropic polypeptide.

J. Malthouse, F. O'Harte, C. Hewage, 2011, Biochimica et biophysica acta.